The sgc8c aptamer is a 41-base DNA oligonucleotide that binds to leukaemia cells with high affinity and specificity. In this work we examined the utility of this aptamer as both a delivery vehicle and an active targeting agent for an inert platinum complex [(1,10-phenathroline)(ethylenediamine)platinum(II)]
Abstract
The sgc8c aptamer is a 41-base DNA oligonucleotide that binds to leukaemia cells with high affinity and specificity. In this work we examined the utility of this aptamer as both a delivery vehicle and an active targeting agent for an inert platinum complex [ (1,10- phenathroline)(ethylenediamine)platinum(II)] 2+ . The aptamer forms a stem-and-loop confirmation as determined by circular dichroism. This conformation is adopted in both water and phosphate buffered saline solutions. The metal complex binds to the aptamer through intercalation into the aptamer's double helical stem with a binding constant of approximately 4.3 × 10 4 M -1 . Binding of the metal complex to the aptamer had a significant effect on the aptamer's global conformation, and increased its melting temperature by 28 o C possibly through lengthening and stiffening of the aptamer stem. The effect of the aptamer on the metal complex's cytotoxicity and cellular uptake was determined using in vitro assays with the target leukaemia cell line CCRF-CEM and the off-target ovarian cancer cell lines A2780 and A2780cp70. The aptamer has little inherent cytotoxicity and when used to deliver the metal complex results in a significant decrease in the metal complex's cytotoxicity and uptake. The reason(s) for the poor uptake and activity may be due to the change in aptamer conformation which affects its ability to recognise leukaemia cells.
Introduction
Platinum-based chemotherapy agents represent one of the most important classes of drug used to combat a range of human cancers [1, 2] . Whilst effective, the six drugs currently on the market display poor selectivity for cancers compared with other rapidly dividing cells within the human body. As a result there has been enormous interest in the development of delivery vehicles for platinum drugs, which are able to either passively or actively target solid tumours, whilst sparing normal tissue from damage [3] [4] [5] .
Aptamers are oligonucleotide-based recognition molecules which can be short single stranded DNA, RNA, or modified nucleic acid fragments (i.e. locked nucleic acid) [6] . These molecules are able to recognise proteins and peptides expressed on the surface of cells in a manner similar to antibodies. Aptamers with appropriate selectivity can be rapidly generated through an in vitro process known as Systematic Evolution of Ligand by EXponential enrichment (SELEX) and offer reduced immunogenicity, good tumour penetration, rapid uptake and clearance, as active targeting groups for drug delivery [7] . In particular, they have the potential to act as cancer targeting molecules as they are able to recognise and bind proteins that are over-expressed on the surface of cancerous cells [8] .
Aptamers can be better targeting agents compared with essential small molecules, like folate or oestrogen, because of their high cell selectivity, are simpler to synthesise and produce than antibodies, have good stability in storage, and have little or no immunogenicity.
To date aptamers have been used successfully as active targeting agents on the outside of liposome-and micelle-like vehicles containing platinum drugs. Because the platinum drugs are sequestered within the delivery vehicle they do not interact or irreversibly bind to the guanosine and adenosine bases of the aptamer [9] [10] [11] [12] . The need for both a separate delivery vehicle and a conjugated targeting aptamer is complicated to construct and control, with respect to particle size and consistent drug loading. We were therefore interested to see if it was possible to discard the delivery vehicle component of the system and instead use the aptamer as both the cancer targeting agent and the delivery vehicle simultaneously.
An aptamer of particular potential for this application is the sgc8c aptamer [13] . This DNAbased aptamer consists of 41 bases and is able to recognise and bind T-cell acute lymphoblastic leukaemia cells with a binding constant of 0.78 nM [13] .
Unfortunately, "normal" platinum drugs, like cisplatin and carboplatin, which form coordination bonds with DNA after aquation of their labile ligands, cannot be used in this manner. These drugs can form irreversible bonds with N7 atom of guanosine and adenosine bases in the aptamer, and therefore not go on to bind cellular DNA. Instead, platinum anticancer complexes which are coordinately saturated with non-labile amine groups are needed. In the last decade several families of platinum complexes that fit this description have been developed and which are able to reversibly bind to double helical DNA [14] [15] [16] .
These platinum(II) complexes have displayed very high cytotoxicity, and are able to overcome drug-resistance in a variety of different cancer cell lines [15] . An example is a trinuclear platinum complex with bridging 1,6-diaminohexane ligands developed by Farrell and co-workers. With its 8 + charge it is highly water soluble and binds strongly, but reversibly, to double stranded DNA [17] . Another inert platinum complex which has displayed potential is (5,6-dimethyl-1,10-phenanthroline)(1S,2S-diaminocyclohexane)platinum(II) (56MESS) which was developed by Aldrich-Wright [18] [19] [20] .
The highly aromatic phenanthroline-based complex is able to intercalate into double stranded DNA, although its mechanism of action is not thought to be related to its DNA binding [21] .
In this paper we report the first attempted use of an aptamer to act simultaneously as both a delivery vehicle and as an active cancer targeting agent. We examine the aptamer's tertiary structure by circular dichroism and 1 H NMR, the binding of the metal complex [(1,10-phenanthroline)(ethylenediamine)platinum(II)] 2+ (PHENEN) to the aptamer, and the effect of the aptamer on the on the metal complex's cytotoxicity and uptake in the ontarget CCRF-CRM leukaemia cell line and the off-target A2780 and A2780/cp70 ovarian carcinoma cell lines. glutamine and 10% (50 mL) fetal bovine serum. All solutions were prepared using water obtained from a Millipore Direct-Q water purification system.
Preparation of Buffers
PBS solutions (10 mM and 100 mM) were produced using a standard method. A 100 mM stock solution of NaCl was prepared in water. This stock solution was then used for the preparation of both 10 mM and 100 mM phosphate solutions, using a mixture of monosodium phosphate and disodium phosphate. For the 10 mM NaCl phosphate buffer, monosodium phosphate (1.8 g) in NaCl stock solution (150 mL) was combined slowly with disodium phosphate (2.1 g) in NaCl stock solution (150 mL) while the pH of the solution was measured until a pH of 7 was attained. This method was employed in the same manner for the preparation of the 100 mM buffer solution. Glycine buffer was prepared by the addition of glycine (0.1 M) to NaCl (0.1 M) with the pH adjusted to 10.5 using NaOH (0.1 M).
Instrumental techniques

UV-Vis spectroscopy
UV-visible spectrometry was carried out on a Cary 50 Bio spectrophotometer between 200-700 nm, with the scan speed set to medium and using a 1 cm quartz cuvette. All samples were analysed at room temperature.
NMR spectroscopy
1 H NMR spectra of the free sgc8c aptamer, the aptamer bound with PHENEN and 2D nuclear overhauser effect spectroscopy (NOESY) of the free aptamer were obtained on either a 400
MHz or 600 MHz Bruker Avance spectrometer in D 2 O at 27 o C with 128-256 scans.
CD spectrophotometry
All CD spectra were measured in a 2 mm quartz cuvette using a Chirascan CD spectrometer at 25 o C. An air background was run followed by a blank sample of water with 2 repeats prior to sample analysis. All samples were prepared to a concentration of 3.4 µM, confirmed by UV, in water, 10 mM or 100 mM PBS solutions. Spectra were recorded from 200-350 nm with 5 repeats, at a step value of 0.5 nm and a time of 3 seconds per step. The N 2 carrier gas flow for the sample was 2 mL min -1 . The binding constant of PHENEN to the sgc8c aptamer was determined using equation 1, where E is the measured ellipticity at each 8 titration point, E 0 is the ellipticity when no PHENEN has been added, E ∞ is the maximum ellipticity, [PHENEN] is the concentration of the metal complex at each titration point and k is the binding constant:
Thermal UV-Vis Spectrometry
Thermal UV spectra were obtained using a Cary spectrophotometer. Spectra were recorded 
In Vitro Testing
Cytotoxicity
The cytotoxicity of PHENEN and the sgc8c aptamer were measured using growth inhibition MTT assays and is reported as their IC 50 concentration in micromolar (µM). Cytotoxicity was determined in the leukaemia cell line CCRF-CEM, and the ovarian cell lines A2780 and A2780/cp70 and compared with cisplatin. In all assays PHENEN was dissolved in water and diluted to the desired concentration (100 µM) using modified RPMI 1640 medium. Cisplatin was dissolved in 3% DMSO/97% RPMI medium and again diluted to the desired concentration (100 µM) using modified RPMI 1640 medium. For assays carried out in the ovarian cell lines a cell density of 1 x 10 3 per well was selected for both the A2780 and A2780/cp70 lines and a cell density of 2 x 10 5 per well for the CCRF-CEM line was used. The ovarian cell lines were grown into flat 96 well plates and incubated for 48 h. Following this, the medium was removed and replaced with either PHENEN or cisplatin solutions at concentrations between 0 to 100 µM. The plates were further incubated for 24 h before the medium and drug were removed, replaced by fresh medium and incubated for a further 48
h. Plates were then fed with fresh medium and MTT solution (50 µL), wrapped in tinfoil and incubated for 4 h. The medium and MTT were removed from the wells leaving the purple MTT-formazan crystals. These were dissolved by addition of DMSO (200 µL) and glycine buffer (25 µL). Plates were then read by their absorbance at 570 nm with the resulting doseresponse curve displaying absorbance (y-axis) with respect to drug concentration in µM (xaxis). The same procedure was employed for measurement of drug cytotoxicity in the leukaemia cell lines but as they were non-adherent, circular bottomed 96 well plates were used, with these being centrifuged at 1,000 g for 5 min to pellet cells prior to removal of medium. Removal of medium was carried out using a fine gauge hypodermic needle (24 G) to prevent removal of the cell pellet. All incubations were undertaken in a 5% CO 2 humidified atmosphere at 37 o C.
Cell Uptake
Selectivity and uptake of PHENEN and PHENEN bound sgc8c aptamer were measured in ontarget leukaemia CCRF-CEM and the off-target ovarian A2780 and A2780/cp70 cell lines. For drug uptake in the adherent ovarian cell lines a cell density of 1x10 6 Cells were washed with ice cold PBS (1 mL) and centrifuged again at 300 rpm for 4 min before the PBS was removed and the cells were digested in 215 µL nitric acid.
The digested leukaemia and ovarian cells were then collected in a microfuge tube and incubated overnight at 65 o C on a heating block. The digest (50 µL) was then diluted 100-fold using water and 0.1% Triton-X100 anionic surfactant. The platinum content of each sample was then determined using inductively coupled plasma mass spectrometry (ICP-MS) and the uptake recorded as picomoles of platinum per 10 6 cells for the mean ± standard error of the mean (SEM) of three wells.
Results and discussion
Aptamer structure
How aptamers recognise and bind to proteins and peptides expressed on the surface of cancer cells is not fully known but is thought to be a function of both their primary sequence and their subsequent three dimensional shapes. The sgc8 aptamer, from which sgc8c is derived is known to be taken into cells via receptor mediated endocytosis [22] . and be the most stable; although this has never been experimentally determined ( Figure 1 and supplementary information). Therefore, before the metal complex [(1,10-phenanthroline)(ethylenediamine)platinum(II)] 2+ (PHENEN) was added to the aptamer, the aptamer's tertiary structure was examined in solution using circular dichroism and
It is known that calf-thymus DNA adopts a typical B-type DNA conformation in solution [25] , with a characteristic positive peak centred around 275 nm, a negative peak centred around 12 DNA aptamer displays a similar CD spectrum with a positive peak around 275 nm, which is indicative of the DNA aptamer strand possessing 10.4 bases per turn and adopting a B-type DNA conformation [25] . The characteristic negative peak at 240 nm of the B-type DNA is
shown to be present but at a lower intensity and slightly higher wavelength, centred around 250 nm. In place of the small negative peak arising at 228 nm for B-type DNA, a strong positive peak is observed for the sgc8c aptamer. This positive peak may be due to the increased amount of expected random coil (non-base-paired) and single stranded bases within the aptamer compared with calf-thymus DNA..
The three-dimensional structure of the aptamer and the conformation adopted are likely key to its molecular recognition properties and use as a drug delivery vehicle. Due to the variety of different environments present within the body (high/low salt concentration and pH) it was of interest to determine whether the aptamer changed structure under different conditions. Of particular importance is its structure in both high and low salt concentrations which represent the conditions found in blood serum (Cl -= 100 mM) and inside cells (Cl -< 20 mM). The CD spectrum of the sgc8c aptamer was therefore examined in both pure water and PBS (Figure 3) . 
Aptamer binding by PHENEN
The metal complex PHENEN ( Figure 4 ) and other 1,10-phenanthroline containing platinum complexes have been known to intercalate into double helical DNA since the 1970s [26] [27] [28] [29] .
The X-ray crystal structure of PHENEN intercalation was first reported by Lippard in 1976 [30] , and a molecular model showing a 3D representation of a 1,10-phenanthroline-based platinum(II) complex intercalating in DNA is given in reference [18] . As a well-studied DNA intercalator, with modest cytotoxicity, PHENEN was therefore chosen as a simple model of a coordinately saturated amine platinum complex for this study. The next step was to therefore determine whether PHENEN is able to intercalate into the stem of the sgc8c aptamer and what effect intercalation had on the aptamer's structure.
Upon intercalation into DNA, the aromatic proton resonances of phenanthroline-based platinum complexes are known to shift significantly upfield in one dimensional 1 H NMR spectra [18, 27, 28] . The binding of PHENEN to the sgc8c aptamer was also analysed by CD spectrophotometry.
Aliquots of PHENEN were added to the sgc8c aptamer in 10 mM NaCl in 0.5 mole equivalent increments up to a ratio of 10-to-1 and the CD spectrum recorded at each step ( Figure 6 ).
The resulting spectra show significant changes in the sgc8c aptamer's conformation upon the addition of PHENEN. A decrease in the peak intensity of both positive peaks and the negative peak is observed. As more PHENEN is added, further changes in the shape of the aptamer's curve are observed. This includes a hypsochromic shift of the positive peak shown from 220 nm to a shorter wavelength; a total shift of 2.5 nm is observed after addition of ten PHENEN equivalents. In addition, the intense negative peak at 250 nm splits, forming two less intense negative peaks at 255 nm and 230 nm. The primary stages of this peak formation can be seen after addition of three equivalents of PHENEN.
The observed reduction in peak intensity is consistent with binding of the PHENEN to the DNA, however, the overall change in the aptamers curve observed with increasing concentration of PEHENEN is indicative of a change to the secondary structure of the aptamer such as unwinding and lengthening of its stem region to accommodate the intercalation of multiple PHENEN molecules. As the CD curve of the aptamer also continues to change after the addition of more than one equivalent of PHENEN, then this is consistent with the occupancy of more than one binding site on the DNA by the platinum complex.
Given the length of the stem and the nearest neighbour exclusion principle [29] , it would be expected that the sgc8c aptamer stem could accommodate up to four PHENEN molecules at a time. The continued changes in the aptamer's CD spectrum at high PHENEN-to-aptamer ratios therefore suggests that the binding of the metal complex to the aptamer is in equilibrium with free PHENEN, with a continual shift to more drug being bound at high PHENEN concentrations.
The change in the CD spectrum with increasing PHENEN concentration was then used to To further confirm binding of PHENEN to the sgc8c aptamer via an intercalation mode, DNA melting experiments were performed using UV spectrophotometry [29] . The free sgc8c aptamer has a very low temperature of melting (Tm = 18. of the strands are unpaired. The result is an already highly stable structure, so the addition of an intercalating ligand can only have a relatively small effect. In contrast, because much of the sgc8c aptamer is most likely in a random coil state, the structure is quite unstable and therefore the addition of an intercalating ligand would be expected to have a significantly bigger effect on its structural stability. An effect that is consistent with the observed increase in Tm for sgc8C.
Aptamer effect on PHENEN cytotoxicity and uptake
The effect of the sgc8c aptamer on the cytotoxicity of PHENEN was examined using the ontarget CCRF-CEM leukaemia cell line and the off-target ovarian carcinoma cell line A2780
and its cisplatin-resistant derivative A2780/cp70 (Table 1) . PHENEN has moderate activity in the CCRF-CEM and A2780/cp70 cell lines but is not able to overcome cisplatin resistance.
The sgc8C aptamer alone is not cytotoxic to CCRF-CEM cells and is poorly active in A2780/cp70, but appears to have some inherent cytotoxicity in the A2780 line. It is not clear why the aptamer has inherent cytotoxicity towards the non-target cells. It is possible that for these cells that it binds to different peptide/proteins compared with the CCRF-CEM target cells, and the binding of these peptides/proteins affects cell growth. Some aptamers have been shown to bind to specific cell receptors and in one case thioaptamers were developed that bind the primary receptor for hyaluronic acid [37] . As this receptor plays an important function in tumour growth, it is possible that sgc8c may also bind similar receptors on the ovarian cancer cells, which may be the cause of their inherent cytotoxicity.
The binding of PHENEN to the sgc8c aptamer decreases the activity of the platinum complex significantly (P < 0.01). Of importance, the sgc8c aptamer has little effect on the cytotoxicity of PHENEN in the off-target ovarian cell lines (P = 0.076), which is not unexpected, but also decreased the cytotoxicity of PHENEN in the on-target cell line.
The loss of PHENEN activity when bound to the aptamer could arise for three different reasons: (1) the conformational changes made to the aptamer upon PHENEN binding means the aptamer is no longer able to recognise and bind leukaemia cells, (2) the PHENEN bound sgc8c aptamer recognises and binds leukaemia cells but they are not internalised by the cell and/or (3) the PHENEN bound sgc8c aptamer recognises, binds and is internalised by the cells, but the PHENEN is not released inside the cell and therefore can't act to induce apoptosis.
To determine which of the three possible reasons is responsible for the loss of cytotoxicity, cellular uptake experiments were conducted using the same three cell lines using the sgc8c aptamer and another aptamer with the reverse sequence of sgc8c. This second aptamer was examined as it should display no selectivity for the CCRF-CEM cells and therefore the uptake results for this aptamer can be used to help differentiate between a lack of cell recognition and surface trapped PHENEN bound aptamer complex.
The cellular uptake result of PHENEN with the sgc8c aptamer demonstrates that in most cases the addition of the aptamer results in a decrease in the uptake of the metal complex.
The only exception is at the 2 hour mark where the aptamer has no discernible ffect on PHENEN uptake in the A2780/cp70 line. Importantly, the decrease in cellular uptake increases over time such that after 4 hours the uptake of PHENEN in the on-target CCRF-CEM line has dropped 19.5% and has dropped in the off-target A2780 and A2780/cp70 lines 21.1 and 10.8%, respectively.
When PHENEN is added to an aptamer with the reverse sequence of sgc8c (sequence given in supplementary information) a similar effect on the metal complex's cytotoxicity and 20 uptake was observed. The reverse sequence aptamer decreases the cytotoxicity of PHENEN by 2.6-fold and the metal complex's cellular uptake by 56%.
Conclusions
In this work we examined the utility of the T-cell leukaemia targeting DNA sgc8c aptamer as a simultaneous delivery vehicle and active targeting agent for the delivery of an aminecoordinately saturated platinum anticancer complex. The sgc8c form a stem-and-loop type conformation although the equilibrium appears to be shifted more towards the random coil state. The metal complex PHENEN binds the sgc8c aptamer via an intercalative mode, which affects the sgc8c's conformation.
The sgc8c aptamer and the reverse sequence aptamer in vitro results taken together suggest that the decrease in PHENEN cytotoxicity in the on-target CCRF-CEM cell line is due to an inability of the sgc8c aptamer to recognise the leukaemia cell lines. If the PHENENaptamer complex was still able to recognise and bind to the cells but remained trapped on the surface of the cells, then it would be expected that the determined cellular platinum content would be higher compared with the free PHENEN uptake. Instead, the results show that the platinum content of the cells decreases, as it does for the reverse aptamer which cannot recognise CCRF-CEM cells.
If this interpretation of the results is correct and the PHENEN bound sgc8C aptamer has lost its ability to recognise leukaemia cells, then it is important to determine why this is the case.
From the structural analysis of the sgc8c aptamer conformation the results indicated that it formed and stem-and-loop structure, but this structure was dynamic with an equilibrium shifted more towards the random coil state. Binding of PHENEN to the aptamer occurs via intercalation which is a process known to lengthen and stiffen helical DNA and prevent strand separation. From these results we therefore hypothesise that the sgc8c aptamer recognises and binds leukaemia cells not in its preferred stem-and-loop conformation, but either binds from a random coil state and adopts a defined conformation upon binding the cell, or it exists in the stem-and-loop conformation but must unwind to then bind the leukaemia cells. When PHENEN is bound to the aptamer it stops either of these processes from occurring leading to reduced cytotoxicity and uptake of the metal complex now that it is sequestered within the aptamer. A comparison of the measured circular dichroism spectra of free sgc8c DNA aptamer in water (orange, solid line) and calf-thymus DNA (purple, dashed line). Calf-thymus DNA is known to form a typical B-type DNA conformation and the similarity of the aptamer's CD spectra is consistent with the formation of a B-type DNA conformation within a part of the aptamer. 
